Beiersdorf divests Bode
This article was originally published in The Rose Sheet
Executive Summary
German personal-care firm Beiersdorf has sold its affiliate Bode Chemie to Paul Hartmann AG for an undisclosed sum, firm says Oct. 20. Bode Chemie, one of "Europe's leading specialists for disinfection, hygiene and skin protection," generated about $93.3 mil. in sales in 2007, Beiersdorf says. Divestiture is in line with firm's strategy to focus on its skin- and beauty-care offerings and "increas[e] its orientation on the growing cosmetics market." Beiersdorf's Thomas-B. Quaas, chairman of the executive board, states: "Beiersdorf can create good prospects for its affiliate by selling it to Hartmann while systematically pursuing its own successful course in the international growth markets for skin and beauty care." Bode Chemie pickup will allow Hartmann to expand its hygiene products range into the infection prevention market
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.